Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method for inducing immunity against tumor in a patient, comprising administering to the patient in a time-staggered manner: (1) autologous tumor cells or allogeneic tumor cells of the same tumor type each treated to prevent their survival after reinfusion; and (2) intact bispecific and/or trispecific antibodies having the following properties of:

(a) binding to a T cell;

(b) binding to at least one antigen on said autologous tumor cell or said allogeneic tumor cell; and

(c) binding via their Fc portion (in the case of bispecific antibodies) or via a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells,

wherein there is a time interval of 1-48 hours between the administration of (1) and the administration of (2).

2. (Currently amended) The method according to claim 1 wherein the administration of said tumor cells is prior to or after the administration of said antibodies ~~and the interval between the administrations is 1 - 48 hours~~.

3. (Previously presented) The method according to claim 1 wherein the interval is 1 - 24 hours.

4. (Previously presented) The method according to claim 1 wherein the antibodies are administered in an amount of about 5 - 500 μg in each infusion.

5. (Previously presented) The method according to claim 1 wherein said Fc receptor-positive cells have an Fcγ receptor I, II, or III.

6. (Previously presented) The method according to claim 5 wherein said antibodies are able to bind to monocytes, makrophages, dendritic cells, "natural killer" cells (NK cells) and/or activated neutrophils being Fcγ receptor I-positive cells.

7. (Previously presented) The method according to claim 1 wherein said antibodies are capable of inducing tumor-reactive complement-binding antibodies and therefore of inducing a humoral immune response.

8. (Previously presented) The method according to claim 1 wherein said antibodies are selected to bind to the T cells via CD2, CD3, CD4, CD5, CD6, CD8, CD28, and/or CD44.

9. (Previously presented) The method according to claim 1 wherein said antibodies are selected so that following their binding to the Fc receptor-positive cells the expression of CD40, CD80, CD86, ICAM-1, and/or LFA-3 being co-stimulatory antigens and/or the secretion of cytokins by the Fc receptor-positive cell is initiated or increased.

10. (Previously presented) The method according to claim 9 wherein the antibodies are selected so that the secretion of IL-1, IL-2, IL-4, IL-6, IL-8, IL-12, INF-γ being cytokins and/or of TNF-α is increased.

11. (Previously presented) The method according to claim 1 wherein said bispecific antibody is selected from the group consisting of an anti-CD3 X anti-tumor-associated antigen antibody, anti-CD4 X anti-tumor-associated antigen antibody, anti-CD5 X anti-tumor-associated antigen antibody, anti-CD6 X anti-tumor-associated antigen antibody, anti-CD8 X anti-tumor-associated antigen antibody, anti-CD2 X anti-tumor-associated antigen antibody, anti-CD28 X anti-tumor-associated antigen antibody, and anti-CD44 X anti-tumor-associated antigen antibody.

12. (Previously presented) The method according to claim 1 wherein said bispecific antibody is selected from one or more of the following combinations of isotypes:

rat-IgG2b/mouse-IgG2a,

rat-IgG2b/mouse-IgG2b,

rat-IgG2b/mouse-IgG3,

rat-IgG2b/human-IgG1,

rat-IgG2b/human-IgG2,

rat-IgG2b/human-IgG3[oriental allotype G3m(st) = binding to protein A],

rat-IgG2b/human-IgG4,

rat-IgG2b/rat-IgG2c,

mouse-IgG2a/human-IgG3[caucasian allotypes G3m(b+g) = no binding to protein A, in the following indicated as *]

mouse-IgG2a/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-IgG2a/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human- IgG3*-[CH2-CH3]

mouse-IgG2a/human-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human- IgG3*-[CH2-CH3]

mouse-[VH-CH1,VL-CL]-human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-[VH-CH1,VL-CL]-human-IgG4/rat-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4[N-terminal region of CH2]-human- IgG3*[C-terminal region of CH2: > aa position 251]-human- IgG3*[CH3]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge-CH2-CH3]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG2-[hinge-CH2-CH3]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG3-[hinge-CH2-CH3, oriental allotype]

rat-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG4-[hinge-CH2-CH3]

human-IgG1/human-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG2[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG2[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG2/human-[VH-CH1,VL-CL]-human-IgG2-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG4/human-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG3*-[CH2-CH3]

human-IgG4/human-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4[N-terminal region of CH2]-human-IgG3*[C-terminal region of CH2 : > aa position 251]-human-IgG3*[CH3]

mouse-IgG2b/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-IgG2b/human-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-IgG2b/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG3*-[CH2-CH3]

mouse-[VH-CH1,VL-CL]-human-IgG4/rat-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]

human-IgG1/rat-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]

human-IgG1/mouse-[VH-CH1,VL-CL]-human-IgG1-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3]

human-IgG4/human-[VH-CH1,VL-CL]-human-IgG4-[hinge]-human-IgG4-[CH2]-human-IgG3*-[CH3].

13. (Previously presented) The method according to claim 1 wherein said antibody is a heterologous bispecific or trispecific antibody.

14. (Previously presented) The method according to claim 1 wherein the trispecific antibody comprises a T cell binding arm, a tumor cell binding arm and a third specificity for binding to Fc receptor-positive cells.

15. (Previously presented) The method according to claim 14 wherein said trispecific antibody is selected from the group consisting of an anti-CD3 X anti-tumor-associated antigen antibody, anti-CD4 X anti-tumor-associated antigen antibody, anti-CD5 X anti-tumor-associated antigen antibody, anti-CD6 X anti-tumor-associated antigen antibody, anti-CD8 X anti-tumor-associated antigen antibody, anti-CD2 X anti-tumor-associated antigen antibody, anti-CD28 X anti-tumor-associated antigen antibody, and anti-CD44 X anti-tumor-associated antigen antibody.

16. (Previously presented) The method according to claim 1 wherein tumor cells have been treated by irradiation or by a chemical substance.

17. (Previously presented) The method according to claim 1 wherein said antibody binds to a surface antigen on said tumor cells, wherein said surface antigen is absent from non-tumor cells or is present in an amount insufficient for destruction of said non-tumor cells by the antibody.

18. (Previously presented) The method according to claim 17 wherein the tumor cells are subjected to a heat pretreatment to increase the immunogenicity.

19. (Previously presented) The method according to claim 17 wherein the surface antigen is heat shock proteins or MHC class I-related MIC molecules.

20. (Previously presented) The method according to claim 19 wherein the heat shock proteins are HSP25, Hsp60 or Hsp70 (Hsp72) or Hsp90 proteins and the MIC molecules are MIC A or MIC B molecules.

21. (Previously presented) The method according to claim 20 wherein the surface antigens are present in an amount of at least 100 and at the most 500,000 per tumor cell.

22. (Previously presented) The method according to claim 21 wherein the antibody is capable of activating Fc receptor-positive cells whereby the expression of cytokins and/or co-stimulatory antigens is initiated or increased.

23. (Previously presented) The method according to claim 1 wherein the time-staggered application of the intact bispecific and/or trispecific antibodies is performed several times.

24. (Previously presented) The method of claim 3, wherein the interval is 1-12 hours.

25. (Previously presented) The method of claim 24, wherein the interval is 1-6 hours.

26. (Previously presented) The method of claim 25, wherein the interval is 1-4 hours.

27. (Previously presented) The method of claim 26, wherein the interval is 2-4 hours.

28. (Previously presented) The method of claim 4, wherein the antibodies are administered in an amount of about 10-300 μg.

29. (Previously presented) The method of claim 28, wherein the antibodies are administered in an amount of about 10-100 μg.

30. (Previously presented) The method of claim 29, wherein the antibodies are administered in an amount of about 10-50 μg.

31. (Previously presented) The method of claim 4, wherein the tumor cells are administered in an amount of about 10^7 - 10^9 cells.

32. (Previously presented) The method of claim 31, wherein the tumor cells are administered in an amount of about 10^8 cells.

33. (Previously presented) The method of claim 13, wherein the heterologous bispecific antibody is a heterologous rat/mouse bispecific antibody.

34. (Previously presented) The method of claim 16, wherein the irradiation is gamma irradiation.

35. (Previously presented) The method of claim 16, wherein the irradiation has a dose of about 50 to 200 Gy.

36. (Previously presented) The method of claim 16, wherein the chemical substance is mitomycin C.

37. (Previously presented) The method of claim 1, wherein the tumor cells are administered in an amount of about 2×10^4 cells.

38. (Previously presented) The method of claim 1, wherein the tumor cells are administered in an amount of about 5,000 cells.